One stock I’m keeping my eye on this festive season is Optos (LSE: OPTS), the Dunfermline-based medical outfit that creates, sells and leases retinal imaging devices around the world.
Optos develops some of the world’s foremost optical diagnostic and treatment devices, and despite its humble beginnings, sells most of its wares in the high-end US market.
It’s true what they say — the eye really is the window of the body. The retina is one of the best early warning systems for conditions like heart disease, and even cancerous cells can be spotted early in retinal tissue.
Optos’s retinal imagery devices can do what others cannot — it is the only system capable of mapping as much as 82% of the retina and its all-important periphery, which is so hard to capture.
And with the release of new device Daytona, which weighs just 25kg and is scaled to fit in smaller doctors’ and optometrist offices, this high level of insight can now affordably be brought to patients around the world.
Optos recently reported annual results showing a 13% jump in underlying revenues, and I believe the company could have further to grow. With the shares making an assault on their all-time high, I still think these shares could play a blinder in the years ahead.
As well as growth, we're also firm advocates of dividend-paying shares here at the Fool, and I highly recommend this special FREE report for investors that we've named "How To Create Dividends For Life".
Mark Rogers has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.